KRAS and serous adenocarcinoma: In human EC cases, KRAS mutations are rarely found in serous carcinoma (3%) but are more prevalent in endometrioid carcinoma (24%) and CS (12%); TP53 mutations are significantly more common in serous carcinoma (88%) and CS (91%) than in endometrioid carcinoma (21%) [36].